The FDA approved Insmed's Brensocatib, the first drug sanctioned to treat non-cystic fibrosis bronchiectasis (NCFB). This milestone brings a new targeted therapy to roughly 500,000 affected Americans and millions globally. Clinical data from Phase III ASPEN trials demonstrated the drug’s efficacy in reducing neutrophilic inflammation, the root cause of bronchiectasis exacerbations. Insmed’s stock surged 17% following the announcement, highlighting strong investor confidence in its blockbuster sales potential. Experts anticipate Brensocatib will redefine the NCFB treatment landscape.